Koh Furugaki
Yokohama, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Plasma cfDNA analysis of alectinib resistance-related gene alterations in the J-ALEX study.
Journal: ESMO open
Published: March 21, 2025
Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK-inhibitor-induced tolerant persister cells in ALK-fusion-positive lung cancer.
Journal: Molecular oncology
Published: January 23, 2024
Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer.
Journal: NPJ precision oncology
Published: September 07, 2023
Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells.
Journal: Anti-cancer drugs
Published: September 14, 2021
Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against RET-fusion-positive non-small cell lung cancer cells.
Journal: Cancer biology & therapy
Published: August 25, 2020
Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model.
Journal: Molecular cancer therapeutics
Published: July 09, 2019
Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate.
Journal: Cancer chemotherapy and pharmacology
Published: July 24, 2018
Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
Journal: BMC cancer
Published: May 10, 2018
Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model.
Journal: Molecular cancer research : MCR
Published: April 03, 2018
Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines.
Journal: BioMed research international
Published: July 05, 2017
Last Updated: 09/26/2026